|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | ZnO、ZnO/ZnS和ZnO/ZnS/α-Fe_2O_3纳米复合材料的光致发光行为及可见光催化活性(英文)显示文摘为了获得用于染料甲基橙(MEO)降解的高效、经济、易得的光催化剂,采用简单的化学合成法在水溶液介质中制备ZnO、ZnO/ZnS和ZnO/ZnS/α-Fe_2O_3纳米复合材料。利用X射线衍射(XRD)和BET技术测定合成材料的物相、结晶度、表面结构和表面行为。X射线衍射结果表明,ZnO、ZnO/ZnS和ZnO/ZnS/α-Fe2O3纳米材料结晶良好。根据XRD谱中各峰的强度,确定纳米复合材料的组成。BET分析表明,所制备的材料具有介孔行为、Ⅳ型(吸附脱附)曲线和H4型迟滞现象。3种材料中,ZnO/ZnS/α-Fe_2O_3复合材料的比表面积最大。利用紫外-可见光谱分析,测定材料的带隙能,光致发光光谱(PL)则用来确定材料的发射行为和表面缺陷。在PL光谱中,ZnO/ZnS的紫外峰强度比ZnO的低,且ZnO/ZnS/α-Fe_2O_3的紫外峰强度更低。与ZnO相比,ZnO/ZnS的可见发射光谱强度增大,且ZnO/ZnS/α-Fe_2O_3的可见发射光谱强度比ZnO/ZnS的更大。所合成的材料被用作染料甲基橙降解的光催化剂。光降解数据表明,3种染料甲基橙降解的光催化剂中ZnO/ZnS/α-Fe_2O_3是最佳的。紫外光发射峰强度的降低和可见光发射强度的增大导致电子和空穴复合减少,因而使得ZnO/ZnS/α-Fe_2O_3具有最高的光催化活性。 | Gaurav HITKARI Sandhya SINGH Gajanan PANDEY | 2018 | Transactions of Nonferrous Metals Society of China2018，28，7： | 3 |
| 2 | Phytochemicals targeting NF-kB signaling:Potential anti-cancer interventions显示文摘Nuclear factor kB(NF-kB)is a ubiquitous regulator of the signalome and is indispensable for various biological cell functions.NF-kB consists of five transcription factors that execute both cytoplasmic and nuclear signaling processes in cells.NF-kB is the only signaling molecule that governs both pro-and antiapoptotic,and pro-and anti-inflammatory responses.This is due to the canonical and non-canonical components of the NF-kB signaling pathway.Together,these pathways orchestrate cancer-related inflammation,hyperplasia,neoplasia,and metastasis.Non-canonical NF-kB pathways are particularly involved in the chemoresistance of cancer cells.In view of its pivotal role in cancer progression,NF-kB represents a potentially significant therapeutic target for modifying tumor cell behavior.Several phytochemicals are known to modulate NF-kB pathways through the stabilization of its inhibitor,IkB,by inhibiting phosphorylation and ubiquitination thereof.Several natural pharmacophores are known to inhibit the nuclear translocation of NF-kB and associated pro-inflammatory responses and cell survival pathways.In view of this and the high degree of specificity exhibited by various phytochemicals for the NF-kB component,we herein present an in-depth overview of these phytochemicals and discuss their mode of interaction with the NF-kB signaling pathways for controlling the fate of tumor cells for cancerdirected interventions. | Akansha Chauhan Asim Ul Islam Hridayesh Prakash Sandhya Singh | 2022 | Journal of Pharmaceutical Analysis2022，12，3： | 2 |
| 3 | Hypoglycemic and antihyperglycemic activity of Aegle marmelos seed extract in normal and diabetic rats显示文摘 | Achyut Narayan Kesari Rajesh Kumar Gupta Santosh Kumar Singh Sandhya Diwakar Geeta Watal | 2006 | Journal of Ethnopharmacology2006，，3： | 1 |
| 4 | Thermomechanical Fatigue Behaviour of a Modified 9Cr-1Mo Ferritic-Martensitic Steel显示文摘 | A. Nagesha R. Kannan R. Sandhya G.V.S. Sastry M.D. Mathew K. Bhanu Sankara Rao Vakil Singh | 2013 | Procedia Engineering2013，，： | 1 |
| 5 | Study of magnetospheric electron density inferred from whistler observations显示文摘 | Sandhya Mishra Singh AK | 2012 | Earth Science India2012，，： | 1 |
| 6 | Laser in dentistry: An innovative tool in modern dental practice显示文摘 | Sanjeev Verma Sandhya Maheshwari Raj Singh Prabhat Chaudhari | 2012 | National Journal of Maxillofacial Surgery2012，，2： | 1 |
| 7 | Small bowel adenocarcinomas in celiac disease follow the CIM-MSI pathway显示文摘 | Frank Bergmann Sandhya Singh Sara Michel Christoph Kahlert Peter Schirmacher Burkhard Helmke Magnus Von Knebel Doeberitz Matthias Kloor Hendrik Bl?ker | 2010 | Oncology Reports2010，，： | 1 |
| 8 | Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine显示文摘Molecular subtypes-based therapies offer new potential framework for desired and precise outcome in clinical settings.Current treatment strategies in colorectal cancer are largely‘one drug fit all’model for patients that display same pathological conditions.However,CRC is a very heterogenous set ofmalignancy that does not support for above criteria.Each subtype displays different pathological and genetic signatures.Based on these features,therapeutic stratification for individual patients may be designed,which may ultimately lead to improved therapeutic outcomes.In this comprehensive review,we have attempted to briefly outline major CRC pathways.A detailed overview of molecular subtypes and their clinical significance has been discussed.Present and futuremethods,governing CRC subtyping in the era of personalized therapywith a special emphasis on CMS subtypes of CRC has been reviewed.Together,discovery and validation of new CRC patient stratification methods,screening for novel therapeutic targets,and enhanced diagnosis of CRC may improve the treatment outcome. | Manish Pratap Singh Sandhya Rai Ashutosh Pandey Nand K.Singh Sameer Srivastava | 2021 | Genes & Diseases2021，8，2： | 1 |
| 9 | De novo sequencing and assembly of Centella asiatica leaf transcriptome for mapping of structural, functional and regulatory genes with special reference to secondary metabolism显示文摘 | Rajender S. Sangwan Sandhya Tripathi Jyoti Singh Lokesh K. Narnoliya Neelam S. Sangwan | 2013 | Gene2013，，1： | 1 |
| 10 | Unsupervised machine learning-based clustering identifies unique molecular signatures of colorectal cancer with distinct clinical outcomes显示文摘Colorectal cancer(CRC)is known to harbor considerable heterogeneity.1 Consequently,it could be hypothesized that similar-appearing tumors might exhibit substantial genetic differences while diverse-appearing tumors may have a similar genetic landscape.2 Due to these differences at the molecular level,they behave or respond differently to therapies as well.CRC progression is a multistep process and involves the accumulation of substantial genetic and epigenetic events in a stage-dependent manner. | Manish Pratap Singh Sandhya Rai Sarvesh K.Gupta Nand K.Singh Sameer Srivastava | 2023 | Genes & Diseases2023，10，6： | 0 |
| 11 | Management of Hypertension:JNC 8 and Beyond显示文摘Hypertension is a leading risk factor for cardiovascular disease,the leading cause of death and morbidity in our society and on a global scale.Major components of cardiovascular disease include stroke,coronary artery disease,heart failure,and chronic kidney disease,in all of which hypertension plays a major role.The risk of these complications increases directly and linearly with systolic blood pressure starting at 115 mmHg.Although usually asymptomatic,hypertension is readily detectable on physical examination and is amenable to both lifestyle modifi cation and pharmacologic treatment in most patients.However,large proportions of the hypertensive population remain undetected and undertreated.Numerous guidelines have been issued during the past few decades to promote detection and optimal therapy.Despite the increase in risk with systolic blood pressure greater than 115 mmHg,the generally accepted threshold for diagnosis and treatment has been systolic blood pressure greater than 139 mmHg and diastolic blood pressure greater than 80 mmHg because until recently treatment to lower levels has been associated with an unfavorable relation between clinical benefi t and harm.In the past several years,new guidelines,advisories,commentaries,and clinical trials have provided evidence for a potential change in current recommendations for the management of hypertension.In this regard,the long-awaited eighth report of the Joint National Committee on the Prevention,Detection,Evaluation,and Treatment of High Blood Pressure recommended patients older than 60 years be treated to a systolic blood pressure of less than 150 mmHg,which has generated considerable controversy and caution.The striking fi ndings of the Systolic Blood Pressure Intervention Trial(SPRINT)have received considerable attention because of the demonstration that intensive therapy to a target systolic blood pressure below 120 mmHg decreases cardiovascular mortality and morbidity more than less intensive treatment to a target systolic blood pressure below 140 mmHg,but this approach is not fully generalizable because the trial excluded patients younger than 50 years and those with diabetes and prior stroke.This article addresses major issues in the management of hypertension,including those in the seventh and eight reports of the Joint National Committee on the Prevention,Detection,Evaluation,and Treatment of High Blood Pressure and subsequent studies,considering maintenance of prior standards as well as the potential application of important new fi ndings. | Ezra A.Amsterdam Sandhya Venugopal Jonathan Bui Balasingam Thevakumar Angela Thinda Sabrina Virk William J.Bommer Aman Khullar Gagan Singh | 2016 | Cardiovascular Innovations and Applications2016，，B09： | 0 |
| 12 | Optimization of ITO/V_(2)O_(5)/Alq3/TPBi/BPhen/LiF/Al Layers Configuration for OLED and Study of Its Optical and Electrical Characteristics显示文摘Nowadays,OLEDs have shown aesthetic potential in smart cards,sensor displays,other electronic devices,sensitive medical devices and signal monitoring etc.due to their wide range of applications like low power consumption,high contrast ratio,speed highly electroluminescent,wide viewing angle and fast response time.In this paper,a highly efficient organic LED ITO/V_(2)O_(5)/Alq3/TPBi/BPhen/LiF/Al with low turn-on voltage and high optically efficiency is presented including electrical and optical characteristics.The simulation of electrical characteristics like current versus applied voltage,current density versus applied voltage,recombination prefactor versus excess carrier density characteristics and optical characteristics like light flux versus current density,light flux versus applied voltage and optical efficiency versus applied voltage has been explained.The physical design,working principle and thickness of different layers along with the process of formation of singlet and triplet excitons are discussed in detail.Here double electron transport layer(ETL),cathode layers are used to enhance the electrical and optical efficiency of OLED.The operating voltage is found to be~3.2 V for the ITO/V_(2)O_(5)/Alq3/TPBi/BPhen/LiF/Al heterostructure based OLED.The designed organic LED has achieved the maximum optical efficiency at 3 V. | Ritu Sandhya Kattayat H.K.Subania S.Z.Hashmi Jasgurpreet Singh P.A.Avi | 2023 | Semiconductor Science and Information Devices2023，5，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员